Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4]
Not Applicable
- Conditions
- patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000020185
- Lead Sponsor
- Diamond study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who meet one of the following criteria are ecluded. 1. Patients treated with insulin 2. Patients with unstable angina 3. Patients with severe liver dysfunction (AST >= 100IU/L or ALT >= 100IU/L) 4. Patients with severe renal dysfunction (eGFR < 45 mL/min/1.73m2) 5. Known hypersensitivity to dapagliflozin 6. Patients who are pregnant, possibly pregnant, or nursing 7. A history of traetment with SGLT2 inhibitors including dapagliflozin 8. Patients disqualified by doctor for any reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes from baseline to day 5-9 in GFR evaluated by inulin clearance
- Secondary Outcome Measures
Name Time Method Changes from baseline to month 6-12 in hepatic fat amount